Legend Biotech (LEGN) Cash & Equivalents (2019 - 2026)
Legend Biotech's (LEGN) quarterly Cash & Equivalents came in at $646.4 million in Q1 2026, down 35.71% YoY from $1.0 billion in Q1 2025, and down 28.33% on a QoQ basis from $901.9 million in Q4 2025.
Legend Biotech (LEGN) Cash & Equivalents (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Cash & Equivalents data on file, last reported at $646.4 million in Q1 2026.
- Quarterly Cash & Equivalents fell 35.71% year-over-year to $646.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646.4 million (down 35.71% YoY) and the FY2025 annual result came in at $901.9 million, up 214.58% from the prior year.
- Cash & Equivalents retreated to $646.4 million in Q1 2026, from $901.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2023 to a low of $266.6 million in Q2 2025.
- A 5-year average of $854.3 million and a median of $901.9 million in 2025 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 214.58% in 2025, down 78.75% in 2025.
- Tracing LEGN's Cash & Equivalents over 5 years: stood at $786.0 million in 2022, then jumped by 62.55% to $1.3 billion in 2023, then tumbled by 77.56% to $286.7 million in 2024, then jumped by 214.58% to $901.9 million in 2025, then fell by 28.33% to $646.4 million in 2026.
- The last three Cash & Equivalents figures came in at $646.4 million (Q1 2026), $901.9 million (Q4 2025), and $278.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 672.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 672.90 Mn |
| Mar 31, 2026 | 646.40 Mn |
| Dec 31, 2025 | 901.90 Mn |
| Sep 30, 2025 | 278.89 Mn |
| Jun 30, 2025 | 266.59 Mn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 286.70 Mn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.16 Bn |
| Dec 31, 2023 | 1.28 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 670.07 Mn |
| Dec 31, 2022 | 786.03 Mn |
| Sep 30, 2022 | 1.03 Bn |
| Jun 30, 2022 | 788.98 Mn |
| Mar 31, 2022 | 377.79 Mn |
| Dec 31, 2021 | 688.94 Mn |
| Sep 30, 2021 | 338.33 Mn |